Clinical Trial Update: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of Doxorubicin Hydrochloride Liposome Injection completed in ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxorubicin Hydrochloride Liposome Injection (liposomal doxorubicin)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Ovarian Epithelial Cancer Recurrent | Phase 1 | Status: COMPLETED